This Project Grant award from the National Institute on Aging's Aging Research Program (CFDA 93.866) provides $2,573,724 to Tulane University to investigate the role and therapeutic potential of the protein perlecan in vascular dementia (VAD). The research aims to determine how age, sex, and environmental factors like hypoxia influence perlecan levels, its cleavage by cathepsin B, and the impact on pericyte coverage and blood-brain barrier integrity - key factors in the development of VAD. The...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $663,000 to the University of Texas Health Science Center at Houston to conduct research on the relationship between cerebral small vessel disease, ischemic stroke, and sex-specific cognitive impairment. The project aims to understand the chronic neurological consequences of small vessel disease following stroke, and whether targeted elimination of senescent cells can improve vascular...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $766,133 to the University of Texas Health Science Center at Houston to conduct research on the mechanisms underlying amyloid-related imaging abnormalities (ARIA) that can occur following anti-amyloid immunotherapy for Alzheimer's disease. The key objectives are to determine the elimination pathway and clearance mechanism for different conformations of anti-amyloid antibodies in...
The National Institute on Aging, part of the Department of Health and Human Services' National Institutes of Health, awarded $3,724,674 under the Aging Research program (CFDA 93.866) to Texas Tech University Health Sciences Center in Lubbock, Texas. The three-year project grant beginning September 15, 2022 will support research into the impacts of microrna-455-3p (miR-455-3p) in Alzheimer's disease. Specifically, the grantee will investigate the neuroprotective effects of overexpressing and...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $1.1M Project Grant to the University of Texas Medical Branch at Galveston (UTMB) for the period of July 15, 2024 to April 30, 2026. The grant supports research to investigate the mechanisms by which amyloid-beta (Aβ) modulates the trans-synaptic spreading of pathological tau in Alzheimer's disease. Specifically, the project aims to determine how Aβ oligomers influence the binding and...
This $640,906 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to elucidate the role of cerebrovascular disease (CVD) processes in contributing to cognitive decline and Alzheimer's disease (AD) pathology. The project aims to utilize advanced neuroimaging techniques to characterize specific CVD factors, such as vascular stiffness and neurovascular flow dynamics, and evaluate their impact on brain tissue integrity and cognition in...
This $429,000 federal Project Grant award under the National Institute on Aging's Aging Research program (CFDA 93.866) supports research at the University of Texas Health Science Center at Houston (UTHealth) to characterize the biochemical and biological properties of misfolded amyloid-beta (Aβ) proteins in the eyes of Alzheimer's disease patients. The research aims to evaluate the potential for these eye-derived misfolded Aβ proteins to induce pathological seeding and spread of Alzheimer's...
This $2,114,698 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research program) will support research at the University of North Texas Health Science Center at Fort Worth to investigate the role of sex and the brain hormone angiotensin II in Alzheimer's disease. The 5-year project aims to determine how sex chromosomes, sex hormones, and brain-derived hormones interact to modulate angiotensin II activation and associated oxidative stress and cognitive...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,859,444 to The University of Texas Health Science Center at San Antonio to investigate the role of the lipid sulfatide in the development of tau pathology associated with Alzheimer's disease and related dementias. The key objectives are to: 1) examine if sulfatide deficiency leads to increased tau phosphorylation, accumulation, and aggregation in oligodendrocytes; 2) determine the...
This federal Project Grant award, valued at $644,881, was issued by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant supports research by the University of Texas Health Science Center at Houston (UTHealth) to investigate a novel blood substitution therapy for treating acute ischemia and stroke-induced blood dyscrasia in aged populations. Key products and services to be delivered under this 5-year grant include: Testing the ability of blood...
The University of Texas Health Science Center at Houston (UTHealth) received a $1,238,672 federal Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) with an award date of September 1, 2023. The grant supports research to examine the pathological role of von Willebrand factor (VWF) within the wall of leptomeningeal arteries and arterioles, and its potential to impair cerebrovascular function and vascular-mediated clearance of amyloid-beta peptides in conditions of amyloidosis. The proposed studies aim to define the mechanisms by which intramural VWF leads to pathological vascular remodeling and impaired amyloid clearance, as well as evaluate the strategy of reducing intramural VWF to mitigate vascular-related pathology in amyloidosis. The research will utilize a combination of human cell culture studies and in vivo studies in transgenic mouse models. If successful, these studies could provide experimental support for therapeutically targeting intramural VWF in conditions of amyloidosis.